Durvalumab is an immunotherapy drug that helps the immune system target cancer cells. Used mainly for non-small cell lung cancer and biliary tract cancer, it is given intravenously, often after chemotherapy or radiation. Patients with unresectable or metastatic disease may benefit most.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends